Janitschke, D.; Nelke, C.; Lauer, A.A.; Regner, L.; Winkler, J.; Thiel, A.; Grimm, H.S.; Hartmann, T.; Grimm, M.O.W. Effect of Caffeine and Other Methylxanthines on Aβ-Homeostasis in SH-SY5Y Cells. Biomolecules2019, 9, 689.; . https://doi.org/10.3390/biom9110689 


Cover Issue Article (IF 4.7)









S.B. Hendrix ; H. Soininen ; A.M.J. van Hees ; N. Ellison ; P.J. Visser ; A. Solomon ; A. Attali ; K. Blennow ; M. Kivipelto ; T. Hartmann (2019): Alzheimer’s Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.33




van Oudenhoven FM, Swinkels SHN, Hartmann T, Soininen H, van Hees AMJ, Rizopoulos D. Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimer's disease with Fortasyn Connect. BMC Med Res Methodol. 2019 Jul 25;19(1):163. doi: 10.1186/s12874-019-0791-z (IF 2.5)




Grimm MOW, Lauer AA, Grösgen S, Thiel A, Lehmann J, Winkler J, Janitschke D, Herr C, Beisswenger C, Bals R, Grimm HS, Hartmann T. Profiling of Alzheimer's disease related genes in mild to moderate vitamin D hypovitaminosis. J Nutr Biochem. 2019 May;67:123-137 (IF 4.4)




Reinhardt S, Schuck F, Stoye N, Hartmann T, Grimm MOW, Pflugfelder G, Endres K. Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease. Cell Mol Life Sci (2019) DOI: 10.1007/s00018-018-2998-2  (IF 6.7)




Coley N, Rosenberg A, Middelaar T, Soulier A, Barbera M, Guillemont J, Steensma J, Igier V, Eskelinen M, Soininen Moll van Charante E, Richard E, Kivipelto M, Andrieu S. Study group: Sindi S, Solomon A, Hartmann T, Brayne C, Gool P,  Beishuizen C, Jongstra S,  van Wanrooij L,  Hoevenaar-Blom M, Ngandu T,  Mangiasche F, Meiller Y and de Groep B Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. JAMDA (2019) J Am Med Dir Assoc. 2019 Jul;20(7):843-849.e5. doi: 10.1016/j.jamda.2018.10.019 (IF 5.3)





Barbero-Camps E, Roca-Agujetas V, Bartolessis I, de Dios C, Fernandez-Checa JC, Montserrat M, Morales A, Hartmann T and Colell A Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion. Autophagy (2018) Jun 4:1-26 doi: 10.1080/15548627.2018.1438807 (IF 8.6)




Verheijen BM, Stevens JAA, Gentier RJG, van’t Hekke CD, van den Hove DLA, Hermes DJHP, Steinbusch HWM, RuijterJM, Grimm MOW, Haupenthal VJ, Annaert W, Hartmann T and van Leuuwen F  Paradoxical effects of mutant ubiquitin on Ab plaque formation in an Alzheimer mouse model. Neurobiology of aging (2018) 72: 62-71 (IF 4.4)




Kivipelto M, Mangialasche F, and Ngandu T (2017) World Wide Fingers will advance dementia prevention. Study group: Eg Nuñez Martín EJJ, Kivipelto M, Ngandu T, Soininen H, Tuomilehto J, Lindström J, Solomon A, Mangialasche F, Sindi S, Baker L, Whitmer R, Espeland M, Du Y, Wang Y, Qiu C, Chen C, Middleton L, Hartmann T. Lancet Neurology 2018 Jan;17(1):27. doi: 10.1016/S1474-4422(17)30431-3 (IF 26.3)







Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, and Hartmann T (2017) 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Study group: Hallikainen I, Hallikainen M, Helisalmi S, Lappalainen T, Liu Y, Paajanen T, Wahlund LO, Freund-Levi Y, Andreasen N, Hagman G, Lindblom S, Fassbender K, Riemenschneider M, Grimm MO, Klees-Rollmann A, Luley M, Lyros E, Schomburg R, Kennel J, Ramelli D, Frölich L, Hausner L, Laske C, Leyhe T, Mychajliw C, Koehler N, Schiekofer S, Klünemann H, Schröder J, Lütjohann D, Scheltens P, van Rossum I, Scheltens N, Bertens D, Ten Kate M, Barkhof F, Henselmans JM, Roks G, van Hees AM, Ellison N. Lancet Neurology 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0 (IF 26.3)




Grimm MOW, Thiel A, Lauer A, Winkler J, Lehmann J, Regner L, Nelke C, Janischke D, Benoist C, Streidenberger O, Stötzel H, Endres K, Herr C, Beisswenger C, Grimm HS, Bals R, Lammert F, Hartmann T (2017) Vitamin D and its analogues decrease Amyloid-β (Aβ) formation and increase Aβ-degradation. Int J Molecular Sciences 2017, 18, 2764 (IF 3,3)




Grimm MOW, Michaelson DM, Hartmann T (2017) Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer’s disease: a rationale for multi-nutrient dementia prevention. J Lipid Res. 2017 (IF 4,4)




Grimm MOW, Mett J, Grimm HS and Hartmann T (2017) APP Function and Lipids: A Bidirectional Link. Front. Mol. Neurosci. 10:63. doi: 10.3389/fnmol.2017.00063 (IF 5.2)




Brandscheid C, Schuck F, Reinhardt S, Schäfer KH, Pietrzik CU, Grimm M, Hartmann T, Schwiertz A, Endres K Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model J Alzheimers Dis.(2017) vol. 56, no. 2, pp. 775-788, 2017 (IF 3,9)










Grimm MO, Regner L , Mett J , Stahlmann CP, Schorr P , Nelke C, Streidenberger O , Stoetzel H, Winkler J, Zaidan SR, Thiel A, Endres K, Grimm HS, Volmer DA  and Hartmann T. Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for Alzheimer’s Disease Int J Mol Sci. 2016, 17, 1809; doi:10.3390/ijms17111809 (IF 3)




Grimm MO, Mett J, Hartmann T. The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease. Int J Mol Sci. 2016 Oct 26;17(11). pii: E1785 (IF 3)




Wittmann A#, Grimm MO#, Scherthan H, Horsch M, Beckers J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Ford SJ, Burton NC, Razansky D, Trümbach D, Aichler M, Walch AK, Calzada-Wack J, Neff F, Wurst W, Hartmann T Ñ, Floss T Ñ. Sphingomyelin Synthase 1 Is Essential for Male Fertility in Mice. PLoS One. 2016 Oct 27;11(10):e0164298. doi: 10.1371/journal.pone.0164298. (IF 3)

# These authors contributed equally to this work. Ñ These authors are joint last authors on this work.




Reinhardt S, Grimm MO, Stahlmann C, Hartmann T, Shudo K, Tomita T, Endres K Rescue of Hypovitaminosis A induces non-amyloidogenic Amyloid Precursor Protein (APP) Processing. Curr Alzheimer Res. 2016 Jun 2. [Epub ahead of print] (IF 1,76)




Endres K, Reinhardt S, Geladaris A, Knies J, Grimm M, Hartmann T, Schmitt U Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neurosci. 2016 Jul 4;17(1):44. doi: 10.1186/s12868-016-0280-9. (IF 2,3)




Hartmann T Verhindern und Verzögern: Implementationsparameter der sekundären Prävention bei der Alzheimer Krankheit. Angewandte Forschung 2016; (4) 28-31




Grimm MOW, Mett J, Stahlmann CP, Haupenthal V, Blümel T, Stötzel H, Grimm HS, Hartmann T Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) increase Aβ-degradation by affecting insulindegrading enzyme (IDE). Biochem Cell Biol, 2016 Dec;94(6):534-542 (IF 2)




Illario M, Maione A, Rusciano M, Goossens E, Rauter A, Braz N, Jager-Wittenaar H, Somma C, Crola C, Soprano M, Vuolo L, Campiglia P, Iaccarino G, Griffiths H, Hartmann T, Tramontano D, Annama Nutrilive: An integrated nutritional approach as a sustainable tool to prevent malnutrition in   older people and promote active and healthy ageing. The EIP-AHA Nutrition Action Group. Adv in Pub Health, Volume 2016, Article ID 5678782, 9 pages http://dx.doi.org/10.1155/2016/5678782




Grimm MO, Haupenthal VJ, Mett J, Stahlmann CP, Blümel T, Mylonas NT, Endres K, Grimm HS, Hartmann T. Oxidized Docosahexaenoic Acid Species and Lipid Peroxidation Products Increase Amyloidogenic Amyloid Precursor Protein Processing. Neurodegener Dis 2016;16:44–54 (IF 3,4)






Mett J, Hartmann T, Grimm MOW. The effects of glycerophospholipids and fatty acids on APP processing: Implications for alzheimer's disease. Handbook of Lipids in Human Function: Fatty Acids, December 04, 2015, Pages 377-421




Blacher E, Dadali T, Bespalko A, Haupenthal VJ, Grimm MO, Hartmann T, Lund FE, Stein R, Levy A. Alzheimer’s disease pathology is attenuated in a CD38 deficient mouse model. Annals in Neurology. 2015 Apr 20. doi: 10.1002/ana.24425 (IF 11,9)




Grimm MO, Stahlmann CP, Mett J, Haupenthal VJ, Zimmer VC, Lehmann J, Hundsdörfer B, Endres K, Grimm HS, Hartmann T. Vitamin E: Curse or Benefit in Alzheimer´s Disease? A Systematic Investigation of the Impact of α-, γ- and δ-Tocopherol on Generation and Degradation in Neuroblastoma Cells. J Nutr Health Aging. 2015;19(6):646-56 (IF 3)




Marcus Otto Grimm, Janine Mett, Christoph Peter Stahlmann, Sven Grösgen, Viola Jessica Haupenthal, Tamara Blümel, Benjamin Hundsdörfer, Valerie Christin Zimmer, Nadine Tamara Mylonas, Heikki Tanila, Ulrike Müller, Heike Sabine Grimm, Tobias Hartmann. APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression. Front. Aging Neurosci. 2015 doi: 10.3389/fnagi.2015.00077 (IF 4,7)






Stahl R, Schilling S, Soba P, Rupp C, Hartmann T, Wagner K, Merdes G, Eggert S, Kins S. Shedding of APP limits its synaptogenic activity and cell adhesion properties. Frontiers in Cellular Neuroscience 11/2014; 8(410). · (IF 4.47)




Grimm MO, Hundsdörfer B, Grösgen S, Mett J, Zimmer VC, Stahlmann CP, Haupenthal VJ, Rothhaar TL, Lehmann J, Pätzold A, Zinser EG, Tanila H, Shen J, Müller U, Grimm HS, Hartmann T. PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer's disease. Cell Physiol Biochem. 2014;34(1):92-110. doi: 10.1159/000362987. Epub 2014 Jun 16. (IF 3.55)




Hartmann T, van Wijk N, Wurtman RJ, Olde Rikkert MGM, Sijben JWC, Soininen H, Vellas B, Scheltens P. A nutritional approach to ameliorate altered phospholipid metabolism in AD. J Alzheimer’s Disease. 2014 Jan 1;41(3):715-7. doi: 10.3233/JAD-141137 (IF 4.2)




Karaca I, Tamboli IY, Glebov K, Richter J, Fell LH, Grimm MO, Haupenthal VJ, Hartmann T, Gräler MH, van Echten-Deckert G, Walter J. Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. J Biol Chem. 2014 May 7 (IF4.7)




Koivisto, Grimm, Rothhaar, Berkecz, Lütjohann, Giniatullina, Takalo, Miettinen, Lahtinen, Giniatullin, Penke, Janáky, Broersen, Hartmann, Tanila. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. J Nutri Biochem 2014 Feb;25(2):157-69. doi: 10.1016/j.jnutbio.2013.09.015. Epub 2013 Nov 6 (IF4.7)




Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T. The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer's Disease. Biomed Res Int. 2013;2013:814390. Epub 2014 (IF2.4)




Robinson, Grösgen, Mett, Zimmer, Haupenthal, Hundsdörfer, Stahlmann, Slobodskoy, Müller, Hartmann, Stein, Grimm. Upregulation of PGC-1α expression by Alzheimer’s disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP. Aging Cell. 2014 Apr;13(2):263-72. doi: 10.1111/acel.12183. Epub 2013 Dec 17. (IF7.55)




Grimm MO, Lehmann J, Mett J, Zimmer VC, Grosgen S, Stahlmann CP, Hundsdorfer B, Haupenthal VJ, Rothhaar TL, Herr C, Bals R, Grimm HS, Hartmann T. Impact of Vitamin D on Amyloid Precursor Protein Processing and Amyloid-beta Peptide Degradation in Alzheimer's Disease. Neurodegener Dis 2014 2014;13(2-3):75-81. doi: 10.1159/000355462. Epub 2013 Oct 30 (IF3.6)




Reinhardt S, Schuck F, Grosgen S, Riemenschneider M, Hartmann T, Postina R, Grimm M, Endres K. Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer’s disease. FASEB J. 2014 Feb;28(2):978-97. doi: 10.1096/fj.13-234864. Epub 2013 Oct 28  (IF5.7)




Hausner L, Tschäpe JA, Schmitt HP, Hentschel F, Hartmann T, Frölich L. Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. Alzheimers Dement. 2014 Mar;10(2):e27-39. doi: 10.1016/j.jalz.2013.02.006. Epub 2013 Jul 11 (IF14.5)






Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci. 2013 Dec 23;5:98. (IF5.2)




Xie K, Liu Y, Hao W, Walter S, Penke B, Hartmann T, Schachner M, Fassbender K. Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice. Neurobiol Aging. 2013 Oct;34(10):2389-98 (IF6.2)




Grimm MOW, Hartmann T. Recent Understanding of the Molecular Mechanisms of Alzheimer’s Disease. J Add Res & Ther 2012 Special Issue: Psychiatric Disorders:1-15. (IF1.33)




Grimm MO, Haupenthal VJ, Rothhaar TL, Zimmer VC, Grösgen S, Hundsdörfer B, Lehmann J, Grimm HS, Hartmann T. Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer's Disease. Int J Mol Sci. 2013 Mar 13;14(3):5879-98 (IF2.5)




Burg, Grimm, Rothhaar, Grösgen, Hundsdörfer, Haupenthal, Zimmer, Mett, Weingärtner, Laufs, Broersen, Tanila, Vanmierlo, Lütjohann,  Hartmann,, Marcus O.W. Grimm. Plant sterols the better cholesterol in Alzheimer´s disease? A mechanistical study, J Neuroscience, 2013; 33:16072-16087 (IF7.3)






Grimm MO, Zinser EG, Grösgen S, Hundsdörfer B, Rothhaar TL, Burg VK, Kaestner L, Bayer TA, Lipp P, Müller U, Grimm HS, Hartmann T. Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer’s disease pathology with ganglioside metabolism. PLoS One, 2012; 7(3):e34095




Rothhaar TL, Grösgen S, Haupenthal VJ, Burg VK, Hundsdörfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO. Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease. ScientificWorldJournal. 2012;2012:141240. (IF 2.3)




Gries M, Davies L, Liu Y, Bachhuber A, Spiegel J, Dillmann U, Hartmann T, Fassbender K, Walter S. Response of Toll-like receptors in experimental Guillain-Barré syndrome: A kinetic analysis. Neurosci Lett. 2012 Jun 19;518(2):154-60 (IF 2.6)




Vanmierlo T, Weingartner O, van der Pol S, Husche C, Kerksiek A, Friedrichs S, Sijbrands E, Steinbusch H, Grimm M, Hartmann T, Laufs U, Bohm M, de Vries HE, Mulder M, Lutjohann D (2012) Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. J Lipid Res. 2012 Apr;53(4):726-35 (IF 4.8)




Grimm MO, Rothhaar TL, Hartmann T. The role of APP proteolytic processing in lipid metabolism. Exp Brain Res. 2012 Apr;217(3-4):365-75




Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K. TLR2 Is a Primary Receptor for Alzheimer’s Amyloid beta Peptide To Trigger Neuroinflammatory Activation. J Immunol. 2012 Feb 1;188(3):1098-107




Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lutjohann D, Broersen LM, Hartmann T, Michaelson DM (2012) The Isoform-Specific Pathological Effects of ApoE4 in vivo are Prevented by a Fish Oil (DHA) Diet and are Modified by Cholesterol. J Alzheimers Dis. 2012;28(3):667-83.




Grimm MO, Rothhaar TL, Grosgen S, Burg VK, Hundsdorfer B, Haupenthal VJ, Friess P, Kins S, Grimm HS, Hartmann T (2011) Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J Nutr Biochem. 2012 Oct;23(10):1214-23. doi: 10.1016/j.jnutbio.2011.06.015. Epub 2011 Dec 29





Hartmann T, Prinetti A (2011) Going the wrong road: Fyn and targeting of amyloid precursor protein to lipid rafts. J Neurochem 118:677-679.




Schäfer KH, Braun A, Semar S, Letiembre M, Klotz M, Klein JC, Grimm MO, Micci MA, Tagliatela G, Liu Y, Fassbender, K, Hartmann T,.  Alzheimers Disease Affects the Enteric Nervous System. Gastroenterology. 2011 May 140 (5) S54-50




Grimm MO, Kuchenbecker J, Grosgen S, Burg VK, Hundsdorfer B, Rothhaar TL, Friess P, de Wilde MC, Broersen LM, Penke B, Peter M, Vigh L, Grimm HS, Hartmann T (2011) Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 286:14028-14039.




Grimm, M.O.W., S. Groesgen, T. L. Rothhaar, V. K. Burg, B. Hundsdoerfer, V. J. Haupenthal, P. Friess, U. Mueller, K. Fassbender, M. Riemenschneider, H. S. Grimm,  T. Hartmann (2011). Intracellular APP domain (AICD) regulates serine-palmitoyl-CoA transferase (SPT) expression and is affected in Alzheimer's disease.  I J Alzheimer's disease 2011, Article ID 695413,1-8




Grimm MO, Grosgen S, Riemenschneider M, Tanila H, Grimm HS, Hartmann T (2011) From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A 1218:7713-7722




Vanmierlo, T., J. Popp, H. Kölsch, S. Friedrichs, F. Jessen, B. Stoffel-Wagner, T. Bertsch, T. Hartmann, W. Maier, K. von Bergmann, H. Steinbusch, M. Mulder, D. Lütjohann (2011) The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease. Acta Psychiatr. Scand: 1-9




Hao, W., Y. Liu, S. Liu, S. Walter, M.O. Grimm, A. J.  Kiliaan, B. Penke, T. Hartmann, C.E. Rübe, M.D. Menger, K. Fassbender (2011). Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain 134, 278-92 (IF 10.2)




Grimm, M.O.W, J. Kuchenbecker, T. L. Rothhaar, S. Grösgen, B. Hundsdörfer, V.K. Burg, P. Friess, U. Müller, H.S.  Grimm, M. Riemenschneider, T. Hartmann, (2011). Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase (AGPS) by amyloid precursor protein (APP) processing and is affected in Alzheimer's disease. J Neurochem 116, 916-25.




Clarke,  N. A.,  T. Hartmann,  E. L. Jones, C. G Ballard,  P. T. Francis, (2011). Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid 40 and tau in patients with intractable unipolar depression. INT J GERIATR PSYCH 26 1283-91




Grösgen, S., M.O. Grimm, P. Friess, T. Hartmann T, (2010) Role of amyloid beta in lipid homeostasis.  Biochim Biophys Acta 1801: 966-974.



Verwey, N.A., W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, P.P. De Deyn, D. Galasko, H. Hampel, T. Hartmann, E. Kapaki, L. Lannfelt, P.D. Mehta, L. Parnetti, A. Petzold, T. Pirttila, L. Saleh, A. Skinningsrud, J.C. Swieten, M.M. Verbeek, J. Wiltfang, S. Younkin, P. Scheltens, and M.A. Blankenstein, (2009). A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem. 46: p. 235-40


Uhrig, M., C. Ittrich, V. Wiedmann, Y. Knyazev, A.  Weninger, M. Riemenschneider, and T.  Hartmann (2009). Novel Relationship between neurogenin 2 and KIAA0125 Revealed by Clustering of Alzheimer Amyloid beta Responsive Genes in Human Neuroblastoma Cells. PLoS One. 2009 Aug 26;4(8):e6779



Uhrig, M., P. Brechlin, O. Jahn, Y. Knyazev, A. Weninger, L. Busia, M. Otto, and T. Hartmann, (2008). Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces the differentiation potential. BMC Medicine 6:38


Tschaepe, J.A., M.O.W. Grimm, H.S. Grimm, and T. Hartmann, (2008). Cholesterol and A beta production: Methods for analysis of altered cholesterol De Novo synthesis. ADVANCES IN ALZHEIMER’S AND PARKINSON’S DISEASE. INSIGHTS, PROGRESS, AND PERSPECIVES (57): 221-230


Nadler, Y., A. Alexandrovich, N. Grigoriadis, T. Hartmann, KS. Rao, E. Shohami, and R. Stein, (2008). Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia 56(5):552-67


Grimm, M.O., H.S. Grimm, I. Tomic, K. Beyreuther, C. Bergmann*, and T. Hartmann*, (2008). Independent Inhibition of Alzheimer Disease {beta}- and {gamma}-Secretase Cleavage by Lowered Cholesterol Levels. J Biol Chem, 283: p. 11302-11.

This work has been awarded with the Steinberg-Krupp price for Alzheimer Research 2009



Zinser, E.G., T. Hartmann, and M.O. Grimm, (2007). Amyloid beta-protein and lipid metabolism. Biochim Biophys Acta, 1768: p. 1991-2001.


Letiembre, M., W. Hao, Y. Liu, S. Walter, I. Mihaljevic, S. Rivest, T. Hartmann, and K. Fassbender, (2007). Innate immune receptor expression in normal brain aging. Neuroscience, 146(1): p. 248-254


Hartmann, T., J. Kuchenbecker, and M.O. Grimm, (2007). Alzheimer's disease: the lipid connection. J Neurochem, 103 Suppl 1: p. 159-70.


Hartmann, T., K. Fassbender, and M.O.W. Grimm, (2007). Alzheimer's disease prevention - The emerging role of lipids and diet. OCL - Oleagineux Corps Gras Lipides 14 (3-4), p. 182-185


Grimm, M.O.W., J. Kuchenbecker, E. Zinser, and T. Hartmann, (2007). Plasmalogens and APP-processing: Method for the analysis of altered plasmalogen. New Trends in Alzheimer and Parkinson Related Disorders: ADPD2007: 161-166


Grimm, M.O., H.S. Grimm, and T. Hartmann, (2007). Amyloid beta as a regulator of lipid homeostasis. Trends Mol Med, 13: p. 337-44.



Tschäpe, J., and T. Hartmann, (2006). Therapeutic Perspectives in Alzheimer's Disease. Rec. Pat. CNS Drug Discov., 1: p. 119-127.


Schneider, A., W. Schulz-Schaeffer, T. Hartmann, J.B. Schulz, and M. Simons, (2006). Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis, 23: p. 573-7.


Oksman, M., H. Iivonen, E. Hogyes, Z. Amtul, B. Penke, I. Leenders, L. Broersen, D. Lutjohann, T. Hartmann, and H. Tanila, (2006). Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis, 23: p. 563-72.


Liu, Z., Y. Ruan, W. Yue, Z. Zhu, T. Hartmann, K. Beyreuther, and D. Zhang, (2006). GM1 up-regulates Ubiquilin 1 expression in human neuroblastoma cells and rat cortical neurons. Neurosci Lett, 407: p. 59-63.


Hartmann, T., (2006). Role of Amyloid Precursor Protein, Amyloid-beta and gamma-Secretase in Cholesterol Maintenance. Neurodegener Dis, 3: p. 305-11.


Grimm, M.O., J.A. Tschape, H.S. Grimm, E.G. Zinser, and T. Hartmann, (2006). Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurol Scand Suppl, 185: p. 27-32.


Yavich, L., M. Oksman, H. Tanila, P. Kerokoski, M. Hiltunen, T. van Groen, J. Puolivali, P.T. Mannisto, A. Garcia-Horsman, E. MacDonald, K. Beyreuther, T. Hartmann, and P. Jakala, (2005). Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis, 20: p. 303-13.


Grimm MOW, Zinser E, Grimm H, Wilk S, Mueller U, Hartmann T (2006) Link between APP-processing, Alzheimer disease and glycosphingolipid metabolism. Journal of Neurochemistry (99): 12-12



Blankenstein MA, Clark C, De Deyn PP, Galasko D, Hartmann T, Hampel H, Kapaki E, Mehta PD, Parnetti L, Pirttila T, Verbeek MM, Wiltfang J, Blennow K (2005) Multicenter comparison of assays for cerebrospinal fluid (CSF) markers for Alzheimer disease. CLINICA CHIMICA ACTA   (355):S175-S175


Fisher A, Brandeis R, Pittel Z, Haring R, Sparks L, Hartmann T, Inestrosa N, Farias G, Bons N, Bar-Ner N, Natan N, Beach TG (2005) M1 muscarinic agonists - Modulation of hallmarks in Alzheimer's disease (AD) and in cerebral amyloid angiopathy (CAA). J Neurological Sci (229): 338-338


Li, W., N. West, E. Colla, O. Pletnikova, J.C. Troncoso, L. Marsh, T.M. Dawson, P. Jakala, T. Hartmann, D.L. Price, and M.K. Lee, (2005). Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A, 102: p. 2162-7.


Levi, O., D. Lutjohann, A. Devir, K. von Bergmann, T. Hartmann, and D.M. Michaelson, (2005). Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J Neurochem, 95: p. 987-97.


Hartmann, T., LIPIDIET, in Nutrition & Ageing, R. D'Amario, Editor. 2005, European Commission: Brussels. p. 19-20.


Hartman, T., (2005). Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. Subcell Biochem, 38: p. 365-80.


Grimm, M.O., H.S. Grimm, A.J. Patzold, E.G. Zinser, R. Halonen, M. Duering, J.A. Tschape, B. De Strooper, U. Muller, J. Shen, and T. Hartmann, (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol, 7: p. 1118-23.


Grimm, M.O., A.J. Paetzold, H.S. Grimm, E.G. Zinser, T. Ruppert, and T. Hartmann, Linking Alzheimer's disease, b-Amyloid, and Lipids: A technical approach., in Amyloid Precursor Protein - A practical approach., W. Xia and H. Xu, Editors. 2005, CRC Press: Boca Raton, FL. p. 129-144.


Duering, M., M.O. Grimm, H.S. Grimm, J. Schroder, and T. Hartmann, (2005). Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging, 26: p. 785-8.



Zha, Q., Y. Ruan, T. Hartmann, K. Beyreuther, and D. Zhang, (2004). GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry, 9: p. 946-52.


Gouras, G., F. LaFerla, G. Strobel, J. Busciglio, C. Almeida, C. Geula, C. Stenh, D. Lee, M. D'Andrea, B. Nagele, R. Takahashi, T. Hartmann, A. LeBlanc, K. Dineley, and A. Koudinov, (2004). Intraneuronal accumulation-more evidence, less controversy? Journal of Alzheimer's Disease, 6: p. 443-449.


Fassbender, K., S. Walter, S. Kuhl, R. Landmann, K. Ishii, T. Bertsch, A.K. Stalder, F. Muehlhauser, Y. Liu, A.J. Ulmer, S. Rivest, A. Lentschat, E. Gulbins, M. Jucker, M. Staufenbiel, K. Brechtel, J. Walter, G. Multhaup, B. Penke, Y. Adachi, T. Hartmann, and K. Beyreuther, (2004). The LPS receptor (CD14) links innate immunity with Alzheimer's disease. Faseb J, 18: p. 203-5.


Echeverria, V., A. Ducatenzeiler, E. Dowd, J. Janne, S.M. Grant, M. Szyf, F. Wandosell, J. Avila, H. Grimm, S.B. Dunnett, T. Hartmann, L. Alhonen, and A.C. Cuello, (2004). Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience, 129: p. 583-92.



Schonknecht, P., J. Pantel, T. Hartmann, E. Werle, M. Volkmann, M. Essig, M. Amann, N. Zanabili, H. Bardenheuer, A. Hunt, and J. Schroder, (2003). Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res, 120: p. 231-8.


Hartmann, T. and K. Beyreuther, Therapeutische Perspektiven der Alzheimer-Demenz, in Lehrbuch der Gerontopsychatrie und -psychotherapie, H. Förstel, Editor. 2003, Thieme: Stuttgart, New York. p. 273-279.


Grziwa, B., M.O. Grimm, C.L. Masters, K. Beyreuther, T. Hartmann and S.F. Lichtenthaler, (2003). The Transmembrane Domain of the Amyloid Precursor Protein in Microsomal Membranes Is on Both Sides Shorter than Predicted. J Biol Chem, 278: p. 6803-6808.


Grimm, H.S., D. Beher, S.F. Lichtenthaler, M.S. Shearman, K. Beyreuther, and T. Hartmann, (2003). gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J Biol Chem, 278: p. 13077-85.


Gamliel, A., C. Teicher, T. Hartmann, K. Beyreuther, and R. Stein, (2003). Overexpression of wild-type presenilin 2 or its familial Alzheimer's disease-associated mutant does not induce or increase susceptibility to apoptosis in different cell lines. Neuroscience, 117: p. 19-28.



Wood, G.B., A.R. Koudinov, T.G. Ohm, K. Yanagisawa, J. McLaurin, G.P. Eckert, W.E. Müller, T. Hartmann, and F. Fahrenholz, (2002). Cholesterol and Alzheimer's disease. Neurobiology of lipids, 1: p. 1-12.


Simons, M., F. Schwarzler, D. Lütjohann, K. von Bergmann, K. Beyreuther, J. Dichgans, H. Wormstall, T. Hartmann, and J.B. Schulz, (2002). Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol, 52: p. 346-50.


Schönknecht, P., D. Lütjohann, J. Pantel, H. Bardenheuer, T. Hartmann, K. von Bergmann, K. Beyreuther, and J. Schröder, (2002). Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett, 324: p. 83-5.


Runz, H., J. Rietdorf, I. Tomic, M. de Bernard, K. Beyreuther, R. Pepperkok, and T. Hartmann, (2002). Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci, 22: p. 1679-89.


Hartmann, T. and K. Beyreuther, Molekulare Pathologie, in Demenzen, K. Beyreuther, et al., Editors. 2002, Thieme Lehrbuch: Stuttgart, New York. p. 99-105.


Grimm, M.O., I. Tomic, and T. Hartmann, (2002). Potential external source of A beta in biological samples. Nat Cell Biol, 4: p. E164-5.


Gamliel, A., C. Teicher, D.M. Michaelson, L. Pradier, T. Hartmann, K. Beyreuther, and R. Stein, (2002). Increased expression of presenilin 2 inhibits protein synthesis. Mol Cell Neurosci, 19: p. 111-24.


Grimm, M.O.W., J. Kuchenbecker, E.G. Zinser, and T. Hartmann, Plasmalogens and APP-Processing: Method for the Analysis of Altered Plasmalogen Homeostasis, in New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007, I. Hanin, et al., Editors. 2008: Salzburg   Austria. p. 312.



Schönknecht, P., J. Pantel, K. Klinga, M. Jensen, T. Hartmann, B. Salbach, and J. Schröder, (2001). Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease. Neurosci Lett, 307: p. 122-4.


Jauss, M., K. Herholz, L. Kracht, J. Pantel, T. Hartmann, M. Jensen, M. Essig, and J. Schroder, (2001). Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients. Eur Arch Psychiatry Clin Neurosci, 251: p. 225-31.


Hartmann, T. and K. Beyreuther, (2001). Alzheimer (Review). Universitas, 56: p. 451-464.


Hartmann, T. and K. Beyreuther, Der unaufhaltsame Zerfall (Review), in Ruperto Carola Forschungsmagazin. 2001. p. 25-31.


Hartmann, T., (2001). Cholesterol, Abeta and Alzheimer's disease (Review). TINS, 24: p. 45-48.


Grimm, H.S., S. Lichtenthaler, K. Beyreuther, and T. Hartmann, Intracellular and secreted Abeta40/42 ratios are differently influenced by APP mutations, in Alzheimer's disease: Advances in Etiology, Pathogenesis and Therapeutics, K. Iqbal, et al., Editors. 2001, wiley. p. 479-486.


Fassbender, K., M. Simons, C. Bergmann, M. Stroick, D. Lütjohann, P. Keller, H. Runz, S. Kühl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther, and T. Hartmann, (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A, 98: p. 5856-61.


Blasko, I., A. Apochal, G. Boeck, T. Hartmann, B. Grubeck-Loebenstein, and G. Ransmayr, (2001). Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis, 8: p. 1094-101.


Bayer, T.A., O. Wirths, K. Majtenyi, T. Hartmann, G. Multhaup, K. Beyreuther, and C. Czech, (2001). Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport (Review). Brain Pathol, 11: p. 1-11.



Schönknecht, P., J. Pantel, E. Werle, T. Hartmann, M. Essig, K. Baudendistel, K. Beyreuther, and J. Schröder, (2000). Cerebrospinal fluid protein levels in the differential diagnosis of Alzheimer's disease. Fortschr Neurol Psychiatr, 68: p. 439-46.


Leloup, C., D.M. Michaelson, A. Fisher, T. Hartmann, K. Beyreuther, and R. Stein, (2000). M1 muscarinic receptors block caspase activation by phosphoinositide 3- kinase- and MAPK/ERK-independent pathways. Cell Death Differ, 7: p. 825-33.


Jensen, M., T. Hartmann, B. Engvall, R. Wang, S.N. Uljon, K. Sennvik, J. Naslund, F. Muehlhauser, C. Nordstedt, K. Beyreuther, and L. Lannfelt, (2000). Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med, 6: p. 291-302.


Ishii, K., F. Mülhauser, U. Liebl, M. Picard, S. Kühl, B. Penke, T. Bayer, M. Wiessler, M. Hennerici, K. Beyreuther, T. Hartmann, and K. Fassbender, (2000). Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase. Faseb J, 14: p. 1485-9.


Culvenor, J.G., C.A. McLean, B.C. Campbell, C.L. Masters, Q.X. Li, P. Jakala, T. Hartmann, and K. Beyreuther, (2000). The Role of NAC in Amyloidogenesis in Alzheimer's Disease. Am J Pathol, 156: p. 734-736.



Jensen, M., J. Schröder, M. Blomberg, B. Engvall, J. Pantel, N. Ida, H. Basun, L.O. Wahlund, E. Werle, M. Jauss, K. Beyreuther, L. Lannfelt, and T. Hartmann, (1999). Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann Neurol, 45: p. 504-11.


Hartmann, T., (1999). Intracellular biology of Alzheimer’s disease amyloid beta peptide (Review). Eur Arch Psychiatry Clin Neurosci, 249: p. 291-8.


Evin, G., G. Reed, J.E. Tanner, Q.X. Li, J.G. Culvenor, S.J. Fuller, H. Wadsworth, D. Allsop, R.V. Ward, E.H. Karran, C.W. Gray, T. Hartmann, S.F. Lichtenthaler, A. Weidemann, K. Beyreuther, and C. Masters, Characterisation of g-secretase candidates from human brain using a new Western blot assay, in Alzheimer’s disease and related disorders, K. Iqbal, et al., Editors. 1999, John Wiley & sons: New York. P. 411-418.


Culvenor, J.G., C.A. McLean, S. Cutt, B.C. Campbell, F. Maher, P. Jakala, T. Hartmann, K. Beyreuther, C.L. Masters, and Q.X. Li, (1999). Non-Abeta component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol, 155: p. 1173-81.


Christie, G., R.E. Markwell, C.W. Gray, L. Smith, F. Godfrey, F. Mansfield, H. Wadsworth, R. King, M. McLaughlin, D.G. Cooper, R.V. Ward, D.R. Howlett, T. Hartmann, S.F. Lichtenthaler, K. Beyreuther, J. Underwood, S.K. Gribble, R. Cappai, C.L. Masters, A. Tamaoka, R.L. Gardner, A.J. Rivett, E.H. Karran, and D. Allsop, (1999). Alzheimer’s disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J Neurochem, 73: p. 195-204.


Blasko, I., F. Marx, E. Steiner, T. Hartmann, and B. Grubeck-Loebenstein, (1999). TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. Faseb J, 13: p. 63-8.


Bayer, T.A., P. Jäkälä, T. Hartmann, R. Egensperger, R. Buslei, P. Falkai, and K. Beyreuther, (1999). Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport, 10: p. 2799-803.


Bayer, T.A., P. Jäkälä, T. Hartmann, L. Havas, C. McLean, J. Culvenor, Q. Li, C.L. Masters, P. Falkai, and K. Beyreuther, (1999). Alpha Synuclein accumulates in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies but not in Alzheimer’s disease beta-amyloid plaque cores. Neuroscience Letters, 266: p. 213-216.



Culvenor, J.G., A. Henry, T. Hartmann, G. Evin, D. Galatis, A. Friedhuber, U.L. Jayasena, J.R. Underwood, K. Beyreuther, C.L. Masters, and R. Cappai, (1998). Subcellular localization of the Alzheimer’s disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid, 5: p. 79-89.



Schröder, J., J. Pantel, N. Ida, M. Essig, K. Baudendistel, T. Hartmann, M. Knopp, C. Masters, and K. Beyreuther, (1997). Cerebral Atrophy and cerebrospinal fluid ß-amyloid in dementia of the Alzheimer’s type: A study with quantitative magnetic resonance imaging. NeuroImage, 5.


Schröder, J., J. Pantel, N. Ida, M. Essig, T. Hartmann, M. Knopp, L. Schad, R. Sandbrink, H. Sauer, C. Masters, and K. Beyreuther, (1997). Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer’s disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry, 6: p. 505-507.


Hartmann, T., S.C. Bieger, B. Brühl, P.J. Tienari, N. Ida, D. Allsop, G.W. Roberts, C.L. Masters, C.G. Dotti, K. Unsicker, and K. Beyreuther, (1997). Distinct sites of intracellular production for Alzheimer’s disease Ab40/42 amyloid peptides. Nat-Med, 3: p. 1016-20.


Allsop, D., G. Christie, C. Gray, S. Holmes, R. Markwell, D. Owen, L. Smith, H. Wadsworth, R.V. Ward, T. Hartmann, S. Lichtenthaler, G. Evin, S. Fuller, E. Tanner, C. Masters, K. Beyreuther, and G.W. Roberts, Studies on the inhibition of the beta-amyloid formation in APP751-transfected IMR-32 cells, and SPA4CT-transfected SH-SY5Y cells, in Alzheimer’s disease, K. Iqbal, et al., Editors. 1997, John Wiley & Sons Ltd. P. 717-728.



Tienari, P., B. De Strooper, E. Ikonen, M. Simons, A. Weidemann, C. Czech, T. Hartmann, N. Ida, G. Multhaup, C. Masters, F. Van Leuven, K. Beyreuther, and C. Dotti, (1996). The b-amyloid domain is essential for axonal sorting of amyloid precursor protein. EMBO J., 16: p. 5218-5229.


Sandbrink, R., T. Hartmann, C. Masters, and K. Beyreuther, (1996). Genes Contributing to Alzheimer’s Disease. Molec Psychiatry, 1: p. 27-40.


Ida, N., T. Hartmann, J. Pantel, J. Schröder, R. Zerfass, H. Förstel, R. Sandbrink, C. Masters, and K. Beyreuther, (1996). Analysis of heterogenous ßA4 peptides in human cerebrospinal fluid and blood by a newly-developed sensitive Western blot assay. J Biol Chem, 271: p. 22908-22914.


Hartmann, T., C. Bergsdorf, R. Sandbrink, P.J. Tienari, G. Multhaup, N. Ida, S. Bieger, T. Dyrks , A. Weidemann, C.L. Masters, and K. Beyreuther, (1996). Alzheimer’s Disease ßA4 Protein Release and APP Sorting Are Regulated by Alternative Splicing. J. Biol. Chem., 271: p. 13208-13214.



Förstl, H., C. Czech, H. Sattel, C. Geiger Kabisch, C. Besthorn, S. Kreger, U. Mönning, T. Hartmann, C. Masters, and K. Beyreuther, (1994). Apolipoprotein E and Alzheimer dementia. Personal results and brief literature review. Nervenarzt, 65: p. 780-6.



Dyrks, T., E. Dyrks, T. Hartmann, C. Masters, and K. Beyreuther, Radicals as Mediators for the Amyloidogenic Transformation of ßA4-bearing APP-Fragments, in Alzheimer’s disease: Advances in Clinical and Basic Research, B. Corain, et al., Editors. 1993, John Wiley & Sons Ltd. P. 497 – 506.


Czech, C., U. Mönning, P.J. Tienari, T. Hartmann, C. Masters, K. Beyreuther, and H. Förstel, (1993). Apolipoprotein E-e4 allele and Alzheimer’s disease. Lancet, 342: p. 1309-1310.



Dyrks, T., E. Dyrks, T. Hartmann, C. Masters, and K. Beyreuther, (1992). Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem, 267: p. 18210-7.